open access

Vol 23, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-04-24
Get Citation

Vascular endothelial growth factor as a marker of endothelial dysfunction in poly- and comorbidity: focus on hypertension, type 2 diabetes mellitus and subclinical hypothyroidism

Valeriya Nemtsova, Olexandr Bilovol, Anna Shalimova
DOI: 10.5603/AH.a2019.0006
·
Arterial Hypertension 2019;23(2):98-104.

open access

Vol 23, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-04-24

Abstract

Background. The goal of our study was to investigate the content and particularities of change of vascular endothelial
growth factor-A (VEGF-A) levels as a marker of endothelial dysfunction (ED) in patients with hypertension
(HT) with or without type 2 diabetes mellitus (T2DM) and with or without subclinical hypothyroidism (SH).

Material and methods. Two hundred and eleven patients with hypertension stage II were divided into 3 groups:
Group 1 — with HT (n = 55); Group 2 — with AH and T2DM (n = 97); Group 3 — with HT, T2DM and SH
(n = 59). The patients in Group 3 were divided into 3 subgroups depending on TSH levels: 3a (n = 26) — TSH
4.0–6.0 mIU/L; 3b (n = 20) — TSH 6.1–8.0 mIU/L; 3c (n = 13) — TSH 8.1–10.0 mIU/L. We evaluated lipids,
carbohydrate metabolism, serum insulin concentration, insulin resistance index — HOMA, and the level of
VEGF-A in plasma.

Results. The levels of VEGF-A in Group 2 was significantly lower vs. Group1 (323.94 ± 22.17 pg/mL
and 413.15 ± 29.02 pg/mL, respectively (p < 0.05)). The patients in Group 3d had lower VEGF-A levels than
the patients in Group 1, but higher than those in Group 2. Among Group 3 patients, the levels of VEGF-A
were the lowest in the 3a subgroup (375.91 ± 19.81 pg/mL), significantly different from 3b and 3c subgroups
(p < 0.05), for which no differences were found (p > 0.05.). In the 3a subgroup VEGF-A levels were significantly
higher than in Group 2 patients (p < 0.05).

Conclusion. These data confirms the hypothesis of increasing ED in hypothyroidism even at the subclinical level.

Abstract

Background. The goal of our study was to investigate the content and particularities of change of vascular endothelial
growth factor-A (VEGF-A) levels as a marker of endothelial dysfunction (ED) in patients with hypertension
(HT) with or without type 2 diabetes mellitus (T2DM) and with or without subclinical hypothyroidism (SH).

Material and methods. Two hundred and eleven patients with hypertension stage II were divided into 3 groups:
Group 1 — with HT (n = 55); Group 2 — with AH and T2DM (n = 97); Group 3 — with HT, T2DM and SH
(n = 59). The patients in Group 3 were divided into 3 subgroups depending on TSH levels: 3a (n = 26) — TSH
4.0–6.0 mIU/L; 3b (n = 20) — TSH 6.1–8.0 mIU/L; 3c (n = 13) — TSH 8.1–10.0 mIU/L. We evaluated lipids,
carbohydrate metabolism, serum insulin concentration, insulin resistance index — HOMA, and the level of
VEGF-A in plasma.

Results. The levels of VEGF-A in Group 2 was significantly lower vs. Group1 (323.94 ± 22.17 pg/mL
and 413.15 ± 29.02 pg/mL, respectively (p < 0.05)). The patients in Group 3d had lower VEGF-A levels than
the patients in Group 1, but higher than those in Group 2. Among Group 3 patients, the levels of VEGF-A
were the lowest in the 3a subgroup (375.91 ± 19.81 pg/mL), significantly different from 3b and 3c subgroups
(p < 0.05), for which no differences were found (p > 0.05.). In the 3a subgroup VEGF-A levels were significantly
higher than in Group 2 patients (p < 0.05).

Conclusion. These data confirms the hypothesis of increasing ED in hypothyroidism even at the subclinical level.

Get Citation

Keywords

arterial hypertension; type 2 diabetes mellitus; subclinical hypothyroidism; endothelial dysfunction; vascular endothelial growth factor

About this article
Title

Vascular endothelial growth factor as a marker of endothelial dysfunction in poly- and comorbidity: focus on hypertension, type 2 diabetes mellitus and subclinical hypothyroidism

Journal

Arterial Hypertension

Issue

Vol 23, No 2 (2019)

Pages

98-104

Published online

2019-04-24

DOI

10.5603/AH.a2019.0006

Bibliographic record

Arterial Hypertension 2019;23(2):98-104.

Keywords

arterial hypertension
type 2 diabetes mellitus
subclinical hypothyroidism
endothelial dysfunction
vascular endothelial growth factor

Authors

Valeriya Nemtsova
Olexandr Bilovol
Anna Shalimova

References (16)
  1. Kuryata OV, Grechanyk MM. [Functional condition of vascular endothelium in patients with coronary heart disease in combination with non-alcoholic fatty liver disease, depending on weight and influence of statin therapy]. Zaporozhye Med J. 2015(1).
  2. Makurina GI. [Study of the vascular endothelium mechanisms activation in patients with psoriasis and arterial hypertension]. Zaporozhye Med J. 2016(94): 19–24.
  3. Smirnova E.N., Shulkina S.G., Schekotov V.V., Antipova A.A. [Vascular endothelial growth factor as a marker of endothelial dysfunction and early kidney damage in patients with metabolic syndrome]. Modern problems of science and education. Sep 2015. https://www.science-education.ru/ru/article/view?id=21800 (2018 Nov 16).
  4. Vural P, Kabaca G, Firat RD, et al. Administration of Selenium Decreases Lipid Peroxidation and Increases Vascular Endothelial Growth Factor in Streptozotocin Induced Diabetes Mellitus. Cell J. 2017; 19(3): 452–460.
  5. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357.
  6. Ministry of the Health of Ukraine. Order of the Ministry of Health of Ukraine dated 22 May.2009 № 356 "On approval of medical aid protocols for patients with endocrine diseases". 2009, May. http://www.moz.gov.ua/ua/portal/dn_20090805_574.html (2009, May 22).
  7. Ministry of the Health of Ukraine. Order of the Ministry of Health of Ukraine dated 21. Dec. 2012 № 1118 "On Approval and Implementation of Medical-Technological Documents for the Standardization of Medical Aid in Type 2 Diabetes". 2012, Dec . https://medprosvita.com.ua/nakaz-moz-ukrayini-vid-21-12-2012-n-1118-pro-zatver/ (2012, Dec. 21).
  8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140–149.
  9. Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4): 215–228.
  10. McQuade C, Skugor M, Brennan DM, et al. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011; 21(8): 837–843.
  11. Asvold BO, Vatten LJ, Nilsen TIL, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156(2): 181–186.
  12. Blankova ZN, Ageev FT, Seredenina EM et al [Hypothyroidism and cardio-vascular diseases]. Russian Med J. 2014(13): 980. https://www.rmj.ru/articles/endokrinologiya/gipotireoz-i-serdechno-sosudistye-zabolevaniya/#ixzz5X3TYvMkE (2018 Nov 16).
  13. Budnevskiy AV, Kravchenko AY, Feskova AA et al. [Dyslipidemia in subclinical hypofunction of the thyroid gland and the effectiveness of its correction by L-thyroxin replacement therapy]. Young Scientist 2014;17(76):138–142. https://moluch.ru/archive/76/12981/ (2018 Nov 16).
  14. Hamidi Shishavan M, Henning RH, van Buiten A, et al. Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin. Sci Rep. 2017; 7(1): 10975.
  15. Wu S, Li X, Zhang H. Effects of metformin on endothelial function in type 2 diabetes. Exp Ther Med. 2014; 7(5): 1349–1353.
  16. de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014; 275(1): 59–70.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl